Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
The Federal Trade Commission is suing to stop Amgen’s acquisition of Horizon Therapeutics. But rather than claiming product overlap, the agency contends Amgen will use its influence to keep at bay competition for Horizon’s products.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sanofi submitted the first unsolicited offer to acquire Horizon Therapeutics, but Amgen ultimately won what became a competitive bidding process. Amgen says Horizon's drug lineup complements its own portfolio of autoimmune and inflammatory disorder products.
Horizon Therapeutics is gaining global rights to an Arrowhead Pharmaceuticals drug for gout. The preclinical drug is the latest RNA interference program that Arrowhead has licensed to a larger pharma company.
The drug, Tepezza, is described as the first-ever drug treatment for thyroid eye disease, a debilitating disease usually treated with surgery.
Horizon Therapeutics has raised $8 million in equity to develop prescription drugs for pain relief, according to a filing with the Securities and Exchange Commission. The company raised the money from 26 investors and made the first sale in December, according to the filing. Horizon labeled the fundraise “Series D Preferred Stock financing.” Horizon has […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.